Skip to main content
Clinical Trials/CTRI/2023/09/057176
CTRI/2023/09/057176
Not yet recruiting
Phase 2

A randomized open-label pilot study to assess the pharmacoeconomic & therapeutic outcome in schizophrenia patients with aripiprazole regimen based on genetic polymorphism - NI

AJIITH XAVIER F0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: F209- Schizophrenia, unspecified
Sponsor
AJIITH XAVIER F
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
AJIITH XAVIER F

Eligibility Criteria

Inclusion Criteria

  • 1\.Schizophrenia patients who will be started on aripiprazole therapy
  • 2\.Patients \>16 years of either gender
  • 3\.Patient or legally authorized representative willing to give informed consent

Exclusion Criteria

  • 1\.Patients with chronic liver or kidney disease
  • 2\.Pregnant and lactating females
  • 3\. History of neurological, neuroendocrine, or other medical conditions known to affect the central nervous system.
  • 4\. Any significant medical condition that has clinically significant interaction with aripiprazole

Outcomes

Primary Outcomes

Not specified

Similar Trials